Overall survival benefit for weekly vs. three-weekly taxanes regimens in advanced breast cancer: A meta-analysis
Authors:
- Davide MauriDavide Mauri
- Konstantinos KamposiorasKKKonstantinos Kamposioras
- Lamprini TsaliLTLamprini Tsali
- Magdalini BristianouMBMagdalini Bristianou
- Antonis ValachisAVAntonis Valachis
- Ioanna KarathanasiIKIoanna Karathanasi
- Christos GeorgiouCGChristos Georgiou
- Nikolaos P. PolyzosNPNikolaos P. Polyzos
- 1 February 2010
- journal article
- review article
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 36 (1) , 69-74
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Multiple-Treatments Meta-analysis of Chemotherapy and Targeted Therapies in Advanced Breast CancerJNCI: Journal of the National Cancer Institute, 2008
- Practical methods for incorporating summary time-to-event data into meta-analysisTrials, 2007
- Measuring inconsistency in meta-analysesBMJ, 2003
- Quantifying heterogeneity in a meta‐analysisStatistics in Medicine, 2002
- Phase II Study of Weekly Docetaxel and Trastuzumab for Patients With HER-2–Overexpressing Metastatic Breast CancerJournal of Clinical Oncology, 2002
- Docetaxel Administered on a Weekly Basis for Metastatic Breast CancerJournal of Clinical Oncology, 2000
- Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer.Journal of Clinical Oncology, 1998
- Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis.Journal of Clinical Oncology, 1994
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986
- The Combination of Estimates from Different ExperimentsBiometrics, 1954